- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
18 result(s) found for: Likelihood ratio.
Displaying page 1 of 1.
| EudraCT Number: 2004-004701-23 | Sponsor Protocol Number: 2104-03 | Start Date*: 2005-03-14 |
| Sponsor Name:Epix Pharmaceuticals, Inc. | ||
| Full Title: Phase II feasibility study to evaluate the safety and efficacy of EP-2104R for Magnetic Resonance Imaging of thrombi in the arterial vasculature and cardiac chambers | ||
| Medical condition: Detection of thrombi in the arterial vasculature and cardiac chambers | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CZ (Completed) DE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-000123-12 | Sponsor Protocol Number: 2020110469 | Start Date*: 2021-06-22 |
| Sponsor Name:Odense University Hospital | ||
| Full Title: PRISMA-PET – Primary Staging of Prostate Cancer: A Randomized Controlled Trial Comparing 18F-PSMA-1007 PET/CT to Conventional Imaging. | ||
| Medical condition: Newly diagnosed prostate cancer, PET/CT scan used to stage newly diagnosed prostate cancer. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: DK (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-009599-11 | Sponsor Protocol Number: 08/0339 | Start Date*: 2011-02-15 |
| Sponsor Name:Joint UCLH/UCL/Royal Free Biomedical Research Unit | ||
| Full Title: Prospective randomised cross over comparison on the physiological response to non-invasive ventilation using either Air O2 or Heliox21 | ||
| Medical condition: Respiratory failure | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2017-004776-56 | Sponsor Protocol Number: AT1-2017 | Start Date*: 2019-03-06 |
| Sponsor Name:Arctic Therapeutics ehf | ||
| Full Title: Phase IIa Biomarker Study to Evaluate the Efficacy, Safety and Tolerability of AT-1 in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) - the AT1-HCCAA study | ||
| Medical condition: Hereditary Cystatin C Amyloid Angiopathy (HCCAA) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: IS (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-001960-31 | Sponsor Protocol Number: 142/2019 | Start Date*: 2019-08-27 | |||||||||||
| Sponsor Name:Turku PET centre | |||||||||||||
| Full Title: Effect of cladribine treatment on microglial activation in the CNS | |||||||||||||
| Medical condition: Multiple sclerosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-004820-24 | Sponsor Protocol Number: COST-EFFECT-CLINIC | Start Date*: 2015-06-02 |
| Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | ||
| Full Title: Cost-effectiveness of different antiretroviral treatment in patients HIV naive. Randomized clinical, not masked, trial comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48... | ||
| Medical condition: in patients HIV naive. Randomized clinical, not masked, trial comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 weeks | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-002513-27 | Sponsor Protocol Number: 200862 | Start Date*: 2014-11-19 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
| Full Title: A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic... | |||||||||||||
| Medical condition: Subjects with severe asthma | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) SK (Completed) BE (Completed) DE (Completed) CZ (Completed) GR (Completed) EE (Completed) ES (Completed) NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-004739-58 | Sponsor Protocol Number: BAN2401-G000-301 | Start Date*: 2019-06-12 | ||||||||||||||||
| Sponsor Name:Eisai Limited | ||||||||||||||||||
| Full Title: A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease | ||||||||||||||||||
| Medical condition: Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2012-001251-40 | Sponsor Protocol Number: MEA115588 | Start Date*: 2012-10-16 |
| Sponsor Name:GlaxoSmithKline Research and Development Limited | ||
| Full Title: MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncon... | ||
| Medical condition: Subjects with severe, refractory, uncontrolled asthma with elevated blood eosinphils | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed) Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2020-003611-10 | Sponsor Protocol Number: 213744 | Start Date*: 2021-07-06 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
| Full Title: A 52-week, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with sev... | |||||||||||||
| Medical condition: Severe uncontrolled asthma with an eosinophilic phenotype | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) CZ (Completed) PL (Completed) IT (Completed) ES (Ongoing) HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-003496-36 | Sponsor Protocol Number: 69HCL17_0843 | Start Date*: 2019-11-06 | ||||||||||||||||
| Sponsor Name:Hospices Civils de Lyon | ||||||||||||||||||
| Full Title: Dosage optimization of piperacillin/tazobactam in ICU patients based on therapeutic drug monitoring of amikacin - OPTIMA | ||||||||||||||||||
| Medical condition: sepsis or septic shock | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-003632-25 | Sponsor Protocol Number: 206713 | Start Date*: 2021-06-24 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
| Full Title: A 52-week, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with sev... | |||||||||||||
| Medical condition: Severe uncontrolled asthma with an eosinophilic phenotype | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) FR (Completed) CZ (Completed) PL (Completed) IT (Completed) ES (Ongoing) IE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-023986-23 | Sponsor Protocol Number: LF-0802 | Start Date*: 2011-05-27 | |||||||||||
| Sponsor Name:Agennix Incorporated | |||||||||||||
| Full Title: OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis | |||||||||||||
| Medical condition: Severe Sepsis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) NL (Ongoing) ES (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-000974-22 | Sponsor Protocol Number: MRX-701 | Start Date*: 2021-01-29 | |||||||||||
| Sponsor Name:Mirum Pharmaceuticals Inc. | |||||||||||||
| Full Title: Randomized, Double-blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects with Biliary Atresia after Hepatoportoenterostomy | |||||||||||||
| Medical condition: Biliary atresia (BA) is a rare, inflammatory condition of the biliary tree that presents in the first weeks of life and leads to bile duct obstruction and consequent liver injury, fibrosis and cirr... | |||||||||||||
|
|||||||||||||
| Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) FR (Completed) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-000838-39 | Sponsor Protocol Number: MHE104317 | Start Date*: 2007-10-11 | |||||||||||
| Sponsor Name:GlaxoSmithKline Resaearch and Development Ltd | |||||||||||||
| Full Title: A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome | |||||||||||||
| Medical condition: Hypereosinophilic Syndrome | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) NO (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) PL (Trial now transitioned) RO (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-001489-17 | Sponsor Protocol Number: SIOPENRNET003 | Start Date*: 2006-11-17 |
| Sponsor Name:St. Anna Kinderkrebsforschung e.V. | ||
| Full Title: High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) | ||
| Medical condition: High Risk Neuroblastoma | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: AT (Completed) ES (Restarted) GB (GB - no longer in EU/EEA) BE (Completed) DK (Restarted) IT (Completed) IE (Completed) HU (Completed) FI (Completed) SI (Completed) PL (Completed) GR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-001476-11 | Sponsor Protocol Number: AL002-2 | Start Date*: 2020-11-12 | |||||||||||
| Sponsor Name:Alector Inc. | |||||||||||||
| Full Title: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AL002 IN PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE | |||||||||||||
| Medical condition: Early Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) PL (Completed) DE (Completed) IT (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-015883-32 | Sponsor Protocol Number: 28431754DIA3005 | Start Date*: 2010-02-18 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin as Monotherapy in the Treatment of Subjects Wit... | |||||||||||||
| Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: LT (Completed) SE (Completed) ES (Completed) IS (Completed) EE (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.